Saturday 17 October 2026
Export NAGE’s income statement to Excel — free account
Niagen Bioscience, Inc.
NAGE Healthcare Biotechnology
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024. In the quarter to June 2026, revenue fell 4.28%, EPS fell 80.0% and free cash flow grew 140.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
2.49
0.09
−3.49%
Follow NAGE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.95 | 18.38 | 27.65 | 34.56 |
+8 more quarters Free account |
P/S ratio |
1.96 | 2.70 | 3.89 | 5.97 | |
P/FCF ratio |
22.09 | 35.64 | 38.17 | 35.23 | |
P/Operating CF |
91.28 | (295.17) | 741.64 | 201.61 | |
P/B ratio |
3.07 | 4.28 | 6.58 | 10.53 | |
Price to Tangible BV |
3.28 | 4.59 | 7.11 | 10.57 | |
EV/Sales |
1.46 | 2.21 | 3.40 | 5.47 | |
EV/EBITDA |
16.26 | 20.61 | 25.82 | 33.96 | |
EV/Operating CF |
31.63 | 65.00 | 32.63 | 31.85 | |
EV/FCF |
16.43 | 29.10 | 33.40 | 32.27 | |
Quick Ratio |
5.00 | 3.49 | 3.74 | 3.21 | |
Current Ratio |
6.50 | 4.61 | 4.86 | 4.12 | |
Net Debt/EBITDA |
(67.35) | (35.64) | (15.12) | (14.51) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.30 | 1.33 | 1.48 | 1.61 | |
Operating CF/Net income |
2.88 | (0.19) | 0.16 | 0.81 | |
Capex/Depreciation |
(0.31) | 19.72 | (0.51) | (0.12) | |
Research and Development Expense of Revenue |
5.08% | 4.71% | 5.05% | 5.28% | |
Selling, General and Administrative Expense of Revenue |
57.41% | 53.76% | 52.87% | 46.78% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.00 | |
Share Based Compensation of Revenue |
5.78% | 5.45% | 5.17% | 5.17% | |
Graham Net Nets |
0.29 | 0.21 | 0.13 | 0.09 | |
Graham Number |
2.16 | 2.36 | 2.24 | 2.32 | |
Earnings Yield |
6.27% | 5.44% | 3.62% | 2.89% | |
Free Cash Flow Yield |
4.53% | 2.81% | 2.62% | 2.84% | |
Revenue per Share |
0.38 | 0.39 | 0.43 | 0.43 | |
Operating CF per Share |
0.03 | (0.01) | 0.01 | 0.05 | |
Capex per Share |
0.00 | 0.07 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | 0.06 | 0.01 | 0.05 | |
Cash per Share |
0.84 | 0.83 | 0.82 | 0.81 | |
Shareholders Equity per Share |
1.04 | 1.03 | 0.97 | 0.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.04 | 1.03 | 0.97 | 0.89 | |
Free Cash Flow |
2.68 | 4.55 | 0.58 | 3.67 | |
Working Capital |
82.74 | 82.30 | 76.89 | 70.90 | |
Capital Expenditures |
(0.09) | 5.74 | (0.10) | (0.02) | |
Net Current Asset Value |
73.73 | 73.12 | 66.93 | 66.15 | |
EV/EBIT |
17.75 | 21.99 | 27.07 | 35.33 | |
Capex to Sales |
0.00 | (0.18) | 0.00 | 0.00 | |
Price to Operating Income |
23.88 | 26.94 | 30.93 | 38.56 | |
| Other line items | |||||
Average Receivables |
9.12 | 10.06 | 8.75 | 7.80 | |
Average Payables |
11.56 | 11.95 | 9.66 | 9.82 | |
Average Inventory |
17.52 | 17.60 | 14.81 | 14.67 | |
Average Assets |
99.06 | 97.83 | 87.34 | 77.33 | |
Average Common Equity |
73.36 | 68.84 | 61.31 | 52.52 |
Columns are period end dates